Search results
Results from the WOW.Com Content Network
Ribonucleotide reductase inhibitors are a family of anti-cancer drugs that interfere with the growth of tumor cells by blocking the formation of deoxyribonucleotides (building blocks of DNA). Examples include: motexafin gadolinium. [1] hydroxyurea [2] fludarabine, cladribine, gemcitabine, tezacitabine, and triapine [3] gallium maltolate ...
A full alphabetical listing is included after the categorical listing. The agents in this list are often combined into chemotherapy agent for polychemotherapy (combination chemotherapy). For example, the CHOP regimen consists of cyclophosphamide , doxorubicin , vincristine and prednisone .
Ribonuclease L or RNase L (for latent), known sometimes as ribonuclease 4 or 2'-5' oligoadenylate synthetase-dependent ribonuclease, is an interferon (IFN)-induced ribonuclease which, upon activation, destroys all RNA within the cell (both cellular and viral) as well as inhibiting mRNA export.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Ribonuclease inhibitor (RI) is a large (~450 residues, ~49 kDa), acidic (pI ~4.7), leucine-rich repeat protein that forms extremely tight complexes with certain ribonucleases. It is a major cellular protein, comprising ~0.1% of all cellular protein by weight, and appears to play an important role in regulating the lifetime of RNA .
6059 24015 Ensembl ENSG00000164163 ENSMUSG00000058355 UniProt P61221 P61222 RefSeq (mRNA) NM_002940 NM_001040876 NM_015751 RefSeq (protein) NP_001035809 NP_002931 NP_056566 Location (UCSC) Chr 4: 145.1 – 145.13 Mb Chr 8: 80.41 – 80.44 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse ATP-binding cassette sub-family E member 1 (ABCE1) also known as RNase L inhibitor (RLI) is an ...
Catalyses the conversion of the amino acid L-asparagine to aspartic acid and thereby reduces the availability of L-asparagine to leukaemic cells. Unlike normal cells, certain types of leukaemic cells do not synthesise L-asparagine, which is essential for cell growth and survival. Acute lymphoblastic leukaemia and lymphoblastic lymphoma.
Antisense drugs are being developed to treat lung cancer, diabetes and diseases such as arthritis and asthma with a major inflammatory component. [67] It shows that the decreased expression of MLLT4 antisense RNA 1 (MLLT4‑AS1) is a potential biomarker and a predictor of a poor prognosis for gastric cancer.